SearchMenu

Media

Latest press releases, media assets and global media contacts

Press release archiveAnnual Report 2024
Close video

Scroll to explore

Latest press releases

For media and investors

13 June 2025

GSK’s RSV vaccine, Arexvy, accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older

12 June 2025

GSK licenses Shigella vaccine candidate to Bharat Biotech for continued development

02 June 2025

Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

29 May 2025

GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio

28 May 2025

PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee

23 May 2025

Blenrep (belantamab mafodotin) combinations receive positive CHMP opinion in relapsed/refractory multiple myeloma

22 May 2025

Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)

19 May 2025

Blenrep (belantamab mafodotin) combinations approved in Japan for treatment of relapsed/refractory multiple myeloma

14 May 2025

GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)

13 May 2025

GSK provides update on belrestotug development programme

08 May 2025

GLISTEN phase III trial results show linerixibat significantly improves cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)

Behind the science

Read our latest articles

‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’

‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options

‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’

‘How do we improve trust in prevention? The answer lies closer to home than you might think’

‘We’re aiming to protect even more children’: Research starts on second-generation malaria vaccine to prevent most severe form of disease

‘Cancer doesn’t have to be a deadly disease – it’s our goal to make it curable’

Vaccinations are not just for children: why adult immunisation is a health and economic necessity

‘It’s insidious and it’s getting worse’: AMR and the urgent need for novel antibiotics

Three facts scientists have learned about RSV – and why sharing them could help protect those most at risk

‘Long-acting therapies are no longer the future of HIV treatment – they are the now’

Behind the science magazine
Office Image Person Talking With Co Worker

Media Contacts

Are you a professional journalist with an enquiry for our media team?

Get in touch

Media library

Explore our images and videos for use in the media. 

Scientists Collaborating And Conducting Vaccine Research

Image

Scientists collaborating and conducting vaccine research

Scientist working in Jurong lab

Image

Vaccines manufacturing, Jurong

Man sitting at desk with laptop and computer screen

Image

AI Hub, Kings Cross, London

Manufacturing Employee At Work, Singapore

Image

Manufacturing employee at work, singapore

Stevenage R&D site, UK

Image

Stevenage R&D site, UK

Dame Emma Walmsley

Image

Dame Emma Walmsley

Our media library

In the spotlight

Emma Walmsley

2025 First quarter results announcement

Quarterly results
30 April 2025

We announced our first quarter 2025 results at 07:00 BST, 02:00 EDT on Wednesday 30 April.

Lungs Science Image

2024 Annual Report and Responsible Business Performance Report published

Annual Report 2024
27 February 2025
Emma Walmsley

2024 Full year and fourth quarter results announcement

Quarterly results
05 February 2025

We announced our full year and fourth quarter 2024 results at 07:00 GMT, 02:00 EST on Wednesday 5 February.

Q3 2024 results

2024 Third quarter results announcement

Quarterly results
30 October 2024

We announced our third quarter results at 07:00 GMT, 03:00 EDT on Wednesday 30 October.

CEO Emma Walmsley smiling in orange jacket

2024 Second quarter results announcement​

Quarterly results
31 July 2024

We announced our second quarter 2024 results at 07:00 BST, 02:00 EDT on Wednesday 31 July.

Male scientist and female dressed smartly smiling in a studio

GSK at a glance

Quick facts and figures with a downloadable PDF

GSK at a glance

You might also like

Ware 3 2022 Prodqc 38 Hess

Our leading scientists

Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.

Lab worker carrying out a task

GSK at a glance

We prioritise innovation in specialty medicines and vaccines to prevent and treat disease.

Pregnant woman talking to doctor

Global health

We are changing the trajectory of high burden diseases in lower income countries, with a focus on infectious diseases.

Continue to Careers

_